MAOB and Parkinson disease: We have demonstrated that MAO-B is a key molecular target for suppression of neuroinflammation in both PD and AD, suggesting that reversible MAO-B inhibitors with good biosafety and bioavailability are promising candidate treatments for these neurodegenerative disorders.